Dr. Israel was able to share her experience in value framework in oncology with the bladder cancer community. The idea behind value framework from ASCO is focus is to support informed, shared decision making between doctor and patient. Its goal is to develop and employ a tool that can customize information for each patient, and to remind the physician that the primary responsibility is the patient.
Bone metastasis occurs in a majority of patients with advanced prostate cancer and represents a clinically significant issue in the management of these patients. Patients with bone metastases are at increased risk for skeletal complications, including pathologic fracture, spinal cord compression, and radiation or surgery to the bone, collectively termed skeletal-related events (SREs).1 SREs are associated with not only substantial morbidity but also greater mortality, increased pain, decreased quality of life, and increased treatment costs.2-6
Goran Ahlgren, PhD. discussed the initial results from the phase III prospective randomized trial sponsored by the Scandinavian Prostate Cancer Group, SPCG12. The purpose of this study was to use adjuvant chemotherapy to prolong the survival of men with high risk prostate cancer after radical prostatectomy. The authors hypothesized that, similar to other solid tumors, adjuvant chemotherapy may prolong survival in the adjuvant setting as it does in the metastatic setting.
Linda Patrick-Miller, Ph.D, presented the quality of life analysis from the CHAARTED trial (Chemohormonal androgen ablation randomized trial in prostate cancer (E3805)) including men with metastatic hormone sensitive prostate cancer. A secondary endpoint of the study was to determine whether an increase in disease control with androgen deprivation therapy (ADT) plus docetaxel was associated with a change in quality of life. The study included patient reported outcomes on overall quality of life, disease related symptoms, and treatment related symptoms.